Amneal Pharmaceuticals Added to S&P SmallCap 600® Index
Rhea-AI Summary
Amneal Pharmaceuticals (Nasdaq: AMRX) will be added to the S&P SmallCap 600 Index effective before market open on January 30, 2026. The inclusion reflects the company’s consistent operating and financial performance and places Amneal among select pharma and biotech small-cap peers.
The company said the listing may enhance visibility, broaden its investor base, and is typically associated with increased trading liquidity for affected stocks.
Positive
- Index inclusion effective January 30, 2026
- Potential liquidity boost and broader investor awareness
- Recognition of consistent performance by index screening criteria
Negative
- None.
News Market Reaction
On the day this news was published, AMRX gained 1.15%, reflecting a mild positive market reaction. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $52M to the company's valuation, bringing the market cap to $4.61B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
AMRX is up 1.92% while most close peers (PBH, BHC, HCM, PRGO) show negative moves and INDV is modestly positive, indicating this index inclusion appears more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 27 | Earnings date set | Neutral | +1.9% | Company scheduled Q4 and full-year 2025 earnings release and webcast. |
| Jan 09 | R&D collaboration | Positive | -1.8% | Research collaboration and option agreement for Parkinson’s LRRK2 program KFRX06. |
| Dec 22 | FDA biosimilar OK | Positive | +0.2% | FDA approvals for two denosumab biosimilars referencing Prolia and XGEVA. |
| Dec 09 | FDA drug approval | Positive | +2.0% | FDA approval of epinephrine injection vials for U.S. hospitals and acute care. |
| Dec 05 | Clinical data update | Positive | +2.4% | Positive interim Phase 4 ELEVATE-PD results for CREXONT in Parkinson’s disease. |
Recent fundamentally positive catalysts (FDA approvals, clinical data) have generally been followed by modestly positive price reactions, with one collaboration headline showing a short-term divergence.
Over the last few months, Amneal has reported several operational and pipeline milestones. Positive interim Phase 4 ELEVATE-PD results for CREXONT on Dec 5, 2025 and two FDA approvals in December for denosumab biosimilars and epinephrine injectables all saw small positive next-day price moves. A Parkinson’s collaboration with KeifeRx on Jan 9, 2026 coincided with a short-term decline. An earnings date announcement on Jan 27, 2026 preceded the current strength. Today’s S&P SmallCap 600® inclusion fits a trajectory of improving visibility and growing commercial breadth.
Market Pulse Summary
This announcement places Amneal in the S&P SmallCap 600® Index, a widely followed benchmark for U.S. small-cap stocks that meet criteria for market capitalization, liquidity, sector representation, and profitability. It follows recent FDA approvals, positive Parkinson’s data, and 2025 guidance targeting $3.0B–$3.1B in net revenue and $675M–$685M in adjusted EBITDA. Investors evaluating this development may track trading liquidity, index-related ownership changes, and ongoing delivery against the company’s stated financial objectives.
Key Terms
s&p smallcap 600 index financial
AI-generated analysis. Not financial advice.
BRIDGEWATER, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that it has been added to the S&P SmallCap 600® Index. The inclusion will become effective prior to the opening of trading on Friday, January 30, 2026.
Launched in 1994, the S&P SmallCap 600 Index is one of the most widely followed benchmarks for U.S. small-capitalization equities. The index is commonly used by active managers and small-cap investors seeking exposure to companies that meet disciplined criteria for market capitalization, liquidity, sector representation, and sustained profitability. Amneal’s inclusion reflects the Company’s consistent operating and financial performance and places it among a select group of pharmaceutical and biotechnology companies that meet the index’s screening requirements.
“We are pleased to be included in the S&P SmallCap 600 Index, which reflects the progress we have made executing our strategy and delivering consistent and growing financial performance,” said Tasos Konidaris, Executive Vice President and Chief Financial Officer of Amneal. “We believe this recognition enhances Amneal’s visibility within the investment community and supports the continued expansion of our investor base over time.”
Inclusion in the index is typically associated with increased trading liquidity and broader investor awareness for those seeking a more selective segment of the U.S. small-cap universe.
About Amneal
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, NJ, is a global biopharmaceutical company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of over 290 pharmaceuticals, primarily within the United States. In its Affordable Medicines segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit www.amneal.com and follow us on LinkedIn.
Investor Contact
Anthony DiMeo
VP, Investor Relations
anthony.dimeo@amneal.com
Media Contact
Brandon Skop
Sr. Director, Corporate Communications
brandon.skop@amneal.com
FAQ
When does Amneal (AMRX) join the S&P SmallCap 600 index?
What does the S&P SmallCap 600 inclusion mean for AMRX shareholders?
Why was Amneal (AMRX) added to the S&P SmallCap 600 index?
Will AMRX be added to ETFs and passive funds tracking the S&P SmallCap 600?
How might AMRX's trading volume react after the January 30, 2026 inclusion?
